-
-
关键词:
- 急性淋巴细胞白血病 /
- 免疫治疗 /
- Inotuzumab ozogamicin /
- Blinatumomab /
- 嵌合抗原受体T细胞
Abstract: Adult acute lymphoblastic leukemia is a disease with poor prognosis. In recent years, in addition to the standard chemotherapy and hematopoietic stem cell transplantation, immunotherapy based on monoclonal antibody has played an important role in treating adult acute lymphoblastic leukemia. This review focuses on new immunotherapies for the treatment of adult acute lymphoblastic leukemia. -
-
[1] Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update[J]. Blood Cancer J, 2017, 7(6): e577. doi: 10.1038/bcj.2017.53
[2] Ali S, Moreau A, Melchiorri D, et al. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease[J]. Oncologist, 2020, 25(4): e709-e715. doi: 10.1634/theoncologist.2019-0559
[3] Fujishima N, Uchida T, Onishi Y, et al. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia[J]. Int J Hematol, 2019, 110(6): 709-722. doi: 10.1007/s12185-019-02749-0
[4] Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia[J]. J Clin Oncol, 2010, 28(24): 3880-3889. doi: 10.1200/JCO.2009.26.9456
[5] Hong Z, Wei Z, Xie T, et al. Targeting chemokines for acute lymphoblastic leukemia therapy[J]. J Hematol Oncol, 2021, 14(1): 48. doi: 10.1186/s13045-021-01060-y
[6] Simioni C, Bergamini F, Ferioli M, et al. New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances[J]. Hematol Oncol, 2020, 38(1): 22-33. doi: 10.1002/hon.2678
[7] Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application[J]. Int J Hematol, 2017, 105(5): 549-557. doi: 10.1007/s12185-017-2221-5
[8] Lanza F, Maffini E, Rondoni M, et al. CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults[J]. Cancers, 2020, 12(2): 303. doi: 10.3390/cancers12020303
[9] Jabbour E, Advani A S, Stelljes M, et al. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin[J]. Am J Hematol, 2019, 94(4): 408-416. doi: 10.1002/ajh.25394
[10] Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia[J]. N Engl J Med, 2016, 375(8): 740-753. doi: 10.1056/NEJMoa1509277
[11] Afzali S, Salehi S, Shahi A, et al. B cell modulation strategies in the improvement of transplantation outcomes[J]. Mol Immunol, 2020, 125: 140-150. doi: 10.1016/j.molimm.2020.06.028
[12] Bag-Ozbek A, Hui-Yuen JS. Emerging B-Cell Therapies in Systemic Lupus Erythematosus[J]. Ther Clin Risk Manag, 2021, 17: 39-54. doi: 10.2147/TCRM.S252592
[13] Chevallier P, Huguet F, Raffoux E, et al. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase Ⅱ study[J]. Haematologica, 2015, 100(4): e128-e131. doi: 10.3324/haematol.2014.120220
[14] Advani AS, McDonough S, Coutre S, et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia[J]. Br J Haematol, 2014, 165(4): 504-509. doi: 10.1111/bjh.12778
[15] Einsele H, Borghaei H, Orlowski RZ, et al. The BiTE(bispecific T-cell engager)platform: Development and future potential of a targeted immuno-oncology therapy across tumor types[J]. Cancer, 2020, 126(14): 3192-3201. doi: 10.1002/cncr.32909
[16] Nagorsen D, Kufer P, Baeuerle PA, et al. Blinatumomab: a historical perspective[J]. Pharmacol Ther, 2012, 136(3): 334-342. doi: 10.1016/j.pharmthera.2012.07.013
[17] Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival[J]. J Clin Oncol, 2011, 29(18): 2493-2498. doi: 10.1200/JCO.2010.32.7270
[18] Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab[J]. Blood, 2012, 119(26): 6226-6233. doi: 10.1182/blood-2012-01-400515
[19] Alduailej H, Kanfar S, Bakhit K, et al. Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(9): e560-e568. doi: 10.1016/j.clml.2020.04.008
[20] Maury S, Chevret S, Thomas X, et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia[J]. N Engl J Med, 2016, 375(11): 1044-1053. doi: 10.1056/NEJMoa1605085
[21] Wei G, Wang J, Huang H, et al. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. [J]. J Hematol Oncol, 2017, 10(1): 150. doi: 10.1186/s13045-017-0516-x
[22] Sasaki K, Kantarjian HM, Ravandi F, et al. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia(ALL): Interim Results of a Phase Ⅱ Clinical Trial[J]. Blood, 2016, 128(22): 2783. doi: 10.1182/blood.V128.22.2783.2783
[23] Bazarbachi AH, Yilmaz M, Ravandi F, et al. A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia(ALL): Updated results[J]. J Clin Oncol, 2018, 36(15_suppl): 7041.
[24] Maiti A, Kantarjian HM, Ravandi F, et al. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase Ⅱ Trial[J]. Blood, 2017, 130(Supplement 1): 3876.
[25] Caracciolo D, Riillo C, Ballerini A, et al. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia[J]. J Immunother Cancer, 2021, 9(2): e002026. https://pubmed.ncbi.nlm.nih.gov/33597219/
[26] Gorin NC, Isnard F, Garderet L, et al. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase Ⅱ study[J]. Eur J Haematol, 2013, 91(4): 315-321. https://pubmed.ncbi.nlm.nih.gov/23738686/
[27] Feins S, Kong W, Williams EF, et al. An introduction to chimeric antigen receptor(CAR)T-cell immunotherapy for human cancer[J]. Am J Hematol, 2019, 94(S1): S3-S9. doi: 10.1002/ajh.25418
[28] Park JH, Riviere I, Gonen M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia[J]. N Engl J Med, 2018, 378(5): 449-459. doi: 10.1056/NEJMoa1709919
[29] 花京剩, 张剑, 陈苏宁, 等. CAR-T细胞技术在复发或难治急性淋巴细胞白血病中的临床应用进展[J]. 临床血液学杂志, 2020, 33(1): 78-82. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ202001019.htm
[30] 糜坚青, 田洁. 老年急性淋巴细胞白血病的治疗策略[J]. 临床血液学杂志, 2021, 34(5): 293-297. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ202105001.htm
[31] Santomasso BD, Park JH, Salloum D, et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia[J]. Cancer Discov, 2018, 8(8): 958-971. doi: 10.1158/2159-8290.CD-17-1319
[32] Pan J, Niu Q, Deng B, et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia[J]. Leukemia, 2019, 33(12): 2854-2866. doi: 10.1038/s41375-019-0488-7
[33] Dai H, Wu Z, Jia H, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia[J]. J Hematol Oncol, 2020, 13(1): 10-30. doi: 10.1186/s13045-020-0843-1
[34] Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 439-448. doi: 10.1056/NEJMoa1709866
[35] Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL[J]. Bone Marrow Transplant, 2021, 56(3): 552-566. doi: 10.1038/s41409-020-01134-4
[36] Aldoss I, Khaled SK, Budde E, et al. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment[J]. Curr Oncol Rep, 2019, 21(1): 4. doi: 10.1007/s11912-019-0753-y
[37] 董斐斐, 傅维佳, 秦永文, 等. 嵌合抗原受体T细胞治疗的心血管毒性[J]. 临床心血管病杂志, 2020, 36(1): 83-85. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202001019.htm
[38] Yan Z, Zhang H, Cao J, et al. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment[J]. Front Immunol, 2021, 12: 611366. doi: 10.3389/fimmu.2021.611366
[39] Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor(CAR)T-cell therapy[J]. Ann Oncol, 2021, 32(1): 34-48. doi: 10.1016/j.annonc.2020.10.478
[40] Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med, 2014, 371(16): 1507-1517. doi: 10.1056/NEJMoa1407222
[41] Crowther MD, Svane IM, Met Ö. T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road[J]. Cells, 2020, 9(7): 1588. doi: 10.3390/cells9071588
[42] Giavridis T, van der Stegen S, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade[J]. Nat Med, 2018, 24(6): 731-738. doi: 10.1038/s41591-018-0041-7
[43] Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med, 2018, 24(6): 739-748. doi: 10.1038/s41591-018-0036-4
[44] Santomasso B, Bachier C, Westin J, et al. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden[J]. Am Soc Clin Oncol Educ Book, 2019, 39: 433-444. https://europepmc.org/abstract/MED/31099694
[45] Sarkar RR, Gloude NJ, Schiff D, et al. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia[J]. J Natl Cancer Inst, 2019, 111(7): 719-726. doi: 10.1093/jnci/djy193
[46] Aldoss I, Forman SJ. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy[J]. Blood, 2020, 135(11): 804-813. doi: 10.1182/blood.2019002132
-
计量
- 文章访问数: 1792
- PDF下载数: 1992
- 施引文献: 0
下载: